Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

BRAF; MEK; microphthalmia-associated transcription factor (MITF); histone deacetylase (HDAC)

Cell culture and mouse studies suggest combining MEK and HDAC inhibitors could help treat BRAF-mutant melanoma. An overexpression screen of 15,906 open reading frames in a BRAF-mutant melanoma cell line identified resistance mechanisms to small molecule BRAF, MEK or MAPK inhibitors. Hits from the screen, which included the melanocyte developmental regulator MITF, suggested MAPK and cAMP signaling could mediate resistance to these compounds. In a drug-resistant melanoma cell line, an HDAC inhibitor plus a BRAF or MEK inhibitor decreased MITF expression and cell viability compared with a BRAF or MEK inhibitor alone. Next steps could include animal studies of the combination strategy.

SciBX 6(48); doi:10.1038/scibx.2013.1385
Published online Dec. 19, 2013

Patent and licensing status unavailable

Johannessen, C.M. et al. Nature; published online Nov. 3, 2013;
doi:10.1038/nature12688
Contact: Levi A. Garraway,
Broad Institute of MIT and Harvard, Cambridge, Mass.
e-mail:
levi_garraway@dfci.harvard.edu